Oral or intravenous iron for anemia correction in chronic kidney disease?

Kidney International

Volumn 88, Issue 4, 2015, Pages 673-675

  Drüeke, Tilman B ^a   Massy, Ziad A ^a,b  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; FERRIC ION; FERROUS ION; SACCHARIC ACID;

ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULUS FILTRATION RATE; HEMOSIDEROSIS; HUMAN; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; MEASURED GLOMERULAR FILTRATION RATE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ANEMIA, IRON-DEFICIENCY; CHRONIC KIDNEY FAILURE; COMPLICATION; FEMALE; MALE;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942889564     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.189     Document Type: Note

References (9)

1. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
2. Charytan DM, Pai AB, Chan CT et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015; 26: 1238-1247.
3. Macdougall IC, Bock AH, Carrera F et al. FINDCKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084.
4. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-914.
5. Bailie GR, Larkina M, Goodkin DA et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162-168.
6. Kuo KL, Hung SC, Liu JS et al. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesisstimulating agents: A nationwide database analysis. Nephrol Dial Transplant 2015 (doi:10. 1093/ndt/gfv085).
7. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897-906.
8. Pisani A, Riccio E, Sabbatini M et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial. Nephrol Dial Transplant 2015; 30: 645-652.
9. Ponikowski P, Filippatos G, Colet JC et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Eur J Heart Fail 2015; 17: 329-339.